These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
129 related items for PubMed ID: 12753148
1. Tumor progression in hepatocellular carcinoma: relationship with tumor stroma and parenchymal disease. Lockwood DS, Yeadon TM, Clouston AD, Crawford DG, Fawcett J, Callaghan SA, Gotley DC. J Gastroenterol Hepatol; 2003 Jun; 18(6):666-72. PubMed ID: 12753148 [Abstract] [Full Text] [Related]
2. Myofibroblasts are responsible for collagen synthesis in the stroma of human hepatocellular carcinoma: an in vivo and in vitro study. Faouzi S, Le Bail B, Neaud V, Boussarie L, Saric J, Bioulac-Sage P, Balabaud C, Rosenbaum J. J Hepatol; 1999 Feb; 30(2):275-84. PubMed ID: 10068108 [Abstract] [Full Text] [Related]
3. AROS Is a Significant Biomarker for Tumor Aggressiveness in Non-cirrhotic Hepatocellular Carcinoma. Kwon JH, Ahn KS, Moon YH, Park JY, Wang HJ, Choi KY, Kim G, Joh JW, Lee KG, Kang KJ. J Korean Med Sci; 2015 Sep; 30(9):1253-9. PubMed ID: 26339164 [Abstract] [Full Text] [Related]
6. [Expression of breast cancer resistance protein in liver cirrhosis, hepatocellular carcinoma and peritumoral tissues]. Wang YM, Huang GS, Hui YP, Zhang J. Zhonghua Gan Zang Bing Za Zhi; 2009 Mar; 17(3):227-9. PubMed ID: 19335991 [No Abstract] [Full Text] [Related]
8. Hepatocellular carcinoma cells and their fibrotic microenvironment modulate bone marrow-derived mesenchymal stromal cell migration in vitro and in vivo. Garcia MG, Bayo J, Bolontrade MF, Sganga L, Malvicini M, Alaniz L, Aquino JB, Fiore E, Rizzo MM, Rodriguez A, Lorenti A, Andriani O, Podhajcer O, Mazzolini G. Mol Pharm; 2011 Oct 03; 8(5):1538-48. PubMed ID: 21770423 [Abstract] [Full Text] [Related]
12. [Selective deposition of agrin in the microvasculature of hepatocellular carcinoma: aspects in pathogenesis and differential diagnosis]. Tátrai P. Magy Onkol; 2008 Dec 03; 52(4):379-83. PubMed ID: 19068466 [Abstract] [Full Text] [Related]
13. The expression of transforming growth factor-alpha in cirrhosis, dysplastic nodules, and hepatocellular carcinoma: an immunohistochemical study of 70 cases. Yeh MM, Larson AM, Campbell JS, Fausto N, Rulyak SJ, Swanson PE. Am J Surg Pathol; 2007 May 03; 31(5):681-9. PubMed ID: 17460450 [Abstract] [Full Text] [Related]
14. Platelet-derived growth factor receptor α in hepatocellular carcinoma is a prognostic marker independent of underlying liver cirrhosis. Yu JH, Kim JM, Kim JK, Choi SJ, Lee KS, Lee JW, Chang HY, Lee JI. Oncotarget; 2017 Jun 13; 8(24):39534-39546. PubMed ID: 28465473 [Abstract] [Full Text] [Related]
15. Decreased Expression of ZWINT is Associated With Poor Prognosis in Patients With HCC After Surgery. Yang XY, Wu B, Ma SL, Yin L, Wu MC, Li AJ. Technol Cancer Res Treat; 2018 Jan 01; 17():1533033818794190. PubMed ID: 30198401 [Abstract] [Full Text] [Related]
18. Immunohistochemical angiogenic biomarkers in hepatocellular carcinoma and cirrhosis: correlation with pathological features. Ribeiro OD, Canedo NH, Pannain VL. Clinics (Sao Paulo); 2016 Nov 01; 71(11):639-643. PubMed ID: 27982164 [Abstract] [Full Text] [Related]
19. Hypoxia inducible factor 1α in hepatocellular carcinoma with cirrhosis: Association with prognosis. Wang D, Zhang X, Lu Y, Wang X, Zhu L. Pathol Res Pract; 2018 Dec 01; 214(12):1987-1992. PubMed ID: 30274686 [Abstract] [Full Text] [Related]